Search Results For ''

  • Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial

    Industry Opportunity: Addressing a Critical Unmet Need The fight against blood cancer is evolving, and Imugene Limited (ASX:IMU) is at the forefront of this battle. With a new wave of promising results from its Phase 1b trial, Imugene’s allogeneic off-the-shelf CD19 CAR-T therapy, azer-cel, is demonstrating significant potential for patients with relapsed/refractory diffuse large B-cell

    Read More
    Public
  • MTM Unlocks Breakthrough in Gallium and Germanium Recovery

    A Game-Changer for Critical Metals Supply The global semiconductor and defence industries are facing a critical supply chain challenge, with key materials like gallium (Ga) and germanium (Ge) largely controlled by Chinese exports. MTM Critical Metals (ASX:MTM) has taken a major step towards addressing this issue, achieving high recovery rates of these metals from semiconductor

    Read More
    Public
  • Vinyl Group Expands Media Footprint with Launch of Vinyl Media

    Vinyl Group seizes cultural opportunity with premium publishing expansion Vinyl Group (ASX:VNL) is making bold moves in the Australian media landscape, unveiling a major rebrand and restructure of its media division as Vinyl Media. The company, Australia’s only ASX-listed music entity, is positioning itself as a powerhouse for cultural storytelling, blending premium publishing with audience

    Read More
    Public
  • Memphasys Reaches Key Milestone in Felix™ Clinical Trial, Data Lock Expected Soon

    Advanced Sperm Selection Technology Moves Closer to Market Memphasys Limited (ASX:MEM) has hit a critical milestone in its pivotal clinical trial for the Felix™ System, an innovative sperm selection technology designed for Assisted Reproductive Technology (ART) procedures. With the Last Patient Last Visit (LPLV) now completed, the company is entering the final phase before results

    Read More
    Public
  • Radiopharm’s RAD 101 Shows Promise in Detecting Brain Metastases

    New Imaging Breakthrough Targets Growing Brain Metastases Challenge Brain metastases are becoming increasingly prevalent due to improved cancer treatments extending patient survival. However, accurate detection remains a major clinical challenge. A new study highlights promising results for Radiopharm Theranostics’ (ASX:RAD, NASDAQ: RADX) novel imaging agent, RAD 101 (18F-Pivalate), in detecting brain metastases with high precision.

    Read More
    Public
  • Eureka Expands into All-Age Rental Market with Gladstone Acquisition

    Seizing an Opportunity in Affordable Rentals With home ownership in Australia becoming increasingly out of reach and rental demand surging, the all-age rental sector presents a significant growth opportunity. According to the most recent National Census, nearly 30% of Australians rent their homes, and 85% of these renters are under the age of 55. Eureka

    Read More
    Public